Zydus Lifesciences Limited — Updates, 08-08-2025: Press Release

Zydus Lifesciences secured final USFDA approval for Prucalopride Tablets (1mg & 2mg), targeting chronic idiopathic constipation. This key development unlocks access to a significant US market opportunity, with the drug's annual sales previously reaching USD 18.68 Cr. The approval bolsters Zydus's US product pipeline, enhancing its growth prospects and solidifying its position in a high-demand therapeutic segment. This marks a significant operational expansion for the company.